

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.6	117.9	(53.8-223.9)	Male	3	4.7	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	5	3.8	133.1	(42.9-310.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	114.4	(36.9-267.0)
Female	28	31.9	87.8	(58.3-126.8)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	13	12.0	108.1	(57.5-184.8)	<u>Ovary</u>				
Female	6	9.9	60.5	(22.1-131.7)	Female	3	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	36	33.7	106.8	(74.8-147.8)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.3	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.9	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	111	110.4	100.5	(82.7-121.0)
Female	0	0.5	nc	(nc-nc)	Female	77	97.7	78.8	(62.2-98.5)
<u>Lung and Bronchus</u>									
Male	18	15.1	119.4	(70.7-188.7)					
Female	9	12.5	72.2	(33.0-137.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	24.9	108.6	(71.6-158.0)	Male	5	13.0	38.4	(12.4-89.6)
Female	7	9.0	78.1	(31.3-161.0)	Female	2	9.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	10	12.6	79.4	(38.0-146.1)
Female	85	84.0	101.2	(80.9-125.2)	Female	7	11.3	61.9	(24.8-127.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	8	8.8	90.6	(39.0-178.5)
<u>Colon / Rectum</u>					Female	6	4.4	137.2	(50.1-298.7)
Male	31	37.3	83.1	(56.4-117.9)	<u>Ovary</u>				
Female	30	37.4	80.2	(54.1-114.5)	Female	14	9.1	154.3	(84.3-258.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.0	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.7)
Female	2	1.8	nc	(nc-nc)	Female	10	7.9	126.1	(60.3-231.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	86	94.8	90.8	(72.6-112.1)
Female	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.3	nc	(nc-nc)
Male	10	9.8	101.8	(48.7-187.2)	Female	2	4.0	nc	(nc-nc)
Female	3	6.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.7	nc	(nc-nc)
Male	6	4.1	146.2	(53.4-318.3)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	108.8	(46.9-214.5)
Male	8	7.7	103.8	(44.7-204.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.4	nc	(nc-nc)	Female	18	16.8	107.1	(63.4-169.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	290	322.6	89.9	(79.9-100.9)
Female	1	1.8	nc	(nc-nc)	Female	267	294.3	90.7	(80.2-102.3)
<u>Lung and Bronchus</u>									
Male	49	46.3	105.9	(78.3-140.0)					
Female	40	41.2	97.1	(69.4-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.9	(25.8-186.6)	Male	5	3.9	128.7	(41.5-300.3)
Female	1	2.1	nc	(nc-nc)	Female	6	3.2	188.9	(69.0-411.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	3.6	222.9	(96.0-439.2)
Female	28	26.7	105.0	(69.8-151.8)	Female	5	3.0	167.7	(54.0-391.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	12	9.8	121.9	(62.9-212.9)	<u>Ovary</u>				
Female	12	8.7	138.3	(71.4-241.6)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	24	27.2	88.2	(56.5-131.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.9	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	104	90.1	115.4	(94.3-139.9)
Female	0	0.4	nc	(nc-nc)	Female	84	83.0	101.2	(80.7-125.3)
<u>Lung and Bronchus</u>									
Male	19	12.3	154.3	(92.8-241.0)					
Female	10	10.6	94.7	(45.3-174.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	5	6.0	83.7	(27.0-195.4)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	20.7	82.2	(47.8-131.6)
Female	0	0.1	nc	(nc-nc)	Female	18	19.0	94.9	(56.2-150.0)
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	4	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	35.4	101.8	(71.3-140.9)	Male	15	19.0	79.1	(44.2-130.4)
Female	15	13.4	112.1	(62.7-184.9)	Female	14	15.7	89.3	(48.8-149.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.6	76.2	(24.6-177.9)	Male	4	5.2	nc	(nc-nc)
Female	8	5.9	135.0	(58.1-266.0)	Female	7	4.4	160.0	(64.1-329.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	21	18.1	116.2	(71.9-177.6)
Female	128	137.1	93.4	(77.9-111.0)	Female	15	17.2	87.1	(48.7-143.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.9	102.0	(37.2-222.0)	Male	22	13.6	162.1	(101.5-245.4)
<u>Colon / Rectum</u>					Female	5	6.9	72.6	(23.4-169.5)
Male	48	53.7	89.4	(65.9-118.5)	<u>Ovary</u>				
Female	70	55.0	127.3	(99.2-160.9)	Female	11	14.5	75.8	(37.8-135.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.9	101.4	(46.3-192.4)	Male	19	10.2	187.0	(112.5-292.1)
Female	1	2.6	nc	(nc-nc)	Female	12	11.6	103.1	(53.2-180.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	139	145.1	95.8	(80.6-113.1)
Female	5	2.3	216.6	(69.8-505.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.0	88.8	(38.2-174.9)
Male	14	14.7	95.1	(51.9-159.5)	Female	7	5.8	120.7	(48.3-248.6)
Female	12	9.7	123.3	(63.6-215.4)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.6	150.7	(60.4-310.6)
Male	9	6.2	144.6	(66.0-274.4)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	5	3.8	132.9	(42.8-310.1)
<u>Leukemia</u>					Female	15	12.2	123.1	(68.8-203.0)
Male	16	10.9	146.7	(83.8-238.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.5	83.9	(36.1-165.3)	Female	24	27.9	86.0	(55.1-128.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.9	130.3	(59.5-247.4)	Male	508	474.6	107.0	(97.9-116.8)
Female	2	2.7	nc	(nc-nc)	Female	468	460.1	101.7	(92.7-111.4)
<u>Lung and Bronchus</u>									
Male	72	67.8	106.3	(83.1-133.8)					
Female	69	63.6	108.4	(84.3-137.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.4	135.7	(49.5-295.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	14.3	84.0	(43.3-146.7)
Female	0	0.1	nc	(nc-nc)	Female	6	12.1	49.6	(18.1-107.9)
<u>Lung and Bronchus</u>									
Male	0	2.0	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	13.7	80.1	(40.0-143.4)	Male	7	7.9	89.1	(35.7-183.6)
Female	7	4.9	142.5	(57.1-293.6)	Female	4	6.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.9	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.4	94.0	(37.6-193.6)
Female	75	55.3	135.5	(106.6-169.9)	Female	7	6.7	104.6	(41.9-215.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.7	nc	(nc-nc)
Male	18	21.1	85.5	(50.6-135.1)	<u>Ovary</u>				
Female	20	20.1	99.6	(60.8-153.8)	Female	5	5.8	86.3	(27.8-201.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	6	4.0	150.8	(55.1-328.3)
Female	2	1.0	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	56.0	73.2	(52.5-99.3)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.5	nc	(nc-nc)
Male	6	5.9	100.9	(36.8-219.5)	Female	3	2.1	nc	(nc-nc)
Female	5	3.8	131.5	(42.4-306.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.8	86.6	(27.9-202.0)
Male	4	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.8	nc	(nc-nc)	Female	14	11.1	125.9	(68.8-211.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.8	nc	(nc-nc)	Male	151	188.1	80.3	(68.0-94.1)
Female	0	1.0	nc	(nc-nc)	Female	187	180.6	103.6	(89.2-119.5)
<u>Lung and Bronchus</u>									
Male	25	26.4	94.6	(61.2-139.7)					
Female	23	24.1	95.4	(60.5-143.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.1	97.6	(35.6-212.4)	Male	2	3.5	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	23	23.5	97.8	(62.0-146.7)	Female	0	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	2.5	196.4	(63.3-458.3)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	8	9.5	84.5	(36.4-166.5)	<u>Ovary</u>				
Female	8	8.0	99.8	(43.0-196.7)	Female	0	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	26.2	80.1	(49.5-122.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	5	4.8	104.9	(33.8-244.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	78	85.5	91.2	(72.1-113.8)
Female	0	0.4	nc	(nc-nc)	Female	59	74.9	78.8	(60.0-101.7)
<u>Lung and Bronchus</u>									
Male	14	12.0	116.3	(63.5-195.1)					
Female	11	10.0	110.0	(54.8-196.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	6	5.7	104.7	(38.2-228.0)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	20.6	77.8	(44.4-126.3)
Female	0	0.1	nc	(nc-nc)	Female	18	17.9	100.7	(59.7-159.2)
<u>Lung and Bronchus</u>									
Male	3	2.9	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.9	80.7	(34.7-159.0)	Male	7	5.0	141.1	(56.5-290.7)
Female	3	4.0	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	4.8	124.0	(45.3-269.9)
Female	26	37.9	68.6	(44.8-100.5)	Female	2	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	13	14.9	87.3	(46.4-149.3)	<u>Ovary</u>				
Female	16	17.2	93.2	(53.2-151.3)	Female	4	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	46	37.6	122.4	(89.6-163.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.0	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	7	7.7	91.3	(36.6-188.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	127	126.6	100.3	(83.6-119.3)
Female	0	0.8	nc	(nc-nc)	Female	110	132.3	83.2	(68.3-100.2)
<u>Lung and Bronchus</u>									
Male	19	18.3	104.1	(62.6-162.5)					
Female	17	18.4	92.4	(53.8-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	22.0	86.4	(52.0-135.0)	Male	6	11.2	53.6	(19.6-116.7)
Female	15	9.2	163.2	(91.3-269.2)	Female	7	9.7	72.2	(28.9-148.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	10.9	82.5	(37.6-156.6)
Female	88	84.8	103.8	(83.2-127.9)	Female	13	11.5	112.7	(60.0-192.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	3.5	257.1	(117.3-488.1)	Male	3	7.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	4.4	nc	(nc-nc)
Male	25	33.0	75.8	(49.1-112.0)	<u>Ovary</u>				
Female	40	39.4	101.5	(72.5-138.3)	Female	9	9.2	97.7	(44.6-185.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.2	nc	(nc-nc)	Male	6	6.2	96.9	(35.4-211.0)
Female	1	1.8	nc	(nc-nc)	Female	8	8.3	96.7	(41.6-190.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	67	81.3	82.4	(63.9-104.7)
Female	3	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.6	107.3	(39.2-233.5)
Male	6	8.5	70.6	(25.8-153.6)	Female	0	4.3	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.7	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.1	nc	(nc-nc)
Male	3	6.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.5	76.4	(24.6-178.2)	Female	15	16.7	89.6	(50.1-147.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.0	125.5	(40.4-292.9)	Male	223	279.9	79.7	(69.6-90.8)
Female	1	1.9	nc	(nc-nc)	Female	305	299.3	101.9	(90.8-114.0)
<u>Lung and Bronchus</u>									
Male	38	40.5	93.9	(66.5-128.9)					
Female	49	41.2	119.0	(88.0-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	6.8	176.5	(91.1-308.3)	Male	4	4.5	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.1	170.6	(68.3-351.5)
Female	43	30.6	140.6	(101.8-189.5)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	12	10.8	111.1	(57.4-194.2)	<u>Ovary</u>				
Female	11	9.1	120.8	(60.2-216.2)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	37	29.1	127.2	(89.5-175.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	5	3.3	150.2	(48.4-350.4)	Female	0	0.9	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	5	5.9	84.6	(27.3-197.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	105	99.3	105.8	(86.5-128.1)
Female	0	0.5	nc	(nc-nc)	Female	86	92.5	93.0	(74.4-114.8)
<u>Lung and Bronchus</u>									
Male	10	13.4	74.8	(35.8-137.6)					
Female	4	11.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	5.5	183.0	(87.6-336.6)	Male	4	3.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	28	22.0	127.1	(84.4-183.6)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	11	8.5	130.1	(64.9-232.8)	<u>Ovary</u>				
Female	11	7.3	151.2	(75.4-270.5)	Female	4	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	27	23.5	115.1	(75.8-167.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	6	4.4	136.9	(50.0-297.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.2	nc	(nc-nc)	Male	86	77.1	111.6	(89.2-137.8)
Female	0	0.4	nc	(nc-nc)	Female	77	69.1	111.5	(88.0-139.3)
<u>Lung and Bronchus</u>									
Male	12	10.8	111.4	(57.5-194.5)					
Female	15	9.0	167.2	(93.5-275.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	26	23.9	108.8	(71.1-159.5)	Female	7	3.2	220.4	(88.3-454.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	9	10.3	87.4	(39.9-166.0)	<u>Ovary</u>				
Female	11	10.7	102.7	(51.2-183.8)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	27	25.1	107.7	(70.9-156.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.0	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.2	nc	(nc-nc)	Male	84	86.2	97.4	(77.7-120.6)
Female	1	0.5	nc	(nc-nc)	Female	81	83.0	97.6	(77.5-121.3)
<u>Lung and Bronchus</u>									
Male	8	12.6	63.3	(27.3-124.7)					
Female	8	11.5	69.3	(29.9-136.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	90.7	(36.3-186.9)	Male	3	4.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	30	30.7	97.9	(66.0-139.7)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	14	11.8	118.7	(64.8-199.2)	<u>Ovary</u>				
Female	15	11.3	132.4	(74.1-218.4)	Female	6	3.2	187.2	(68.3-407.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.2	223.4	(72.0-521.2)
Female	0	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	28	31.8	88.0	(58.5-127.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	5	3.3	152.1	(49.0-354.9)	Female	2	1.2	nc	(nc-nc)
Female	6	2.1	282.8	(103.3-615.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	0	3.0	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.1	243.3	(78.4-567.7)	Female	7	6.2	112.4	(45.0-231.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	107	104.9	102.0	(83.6-123.3)
Female	1	0.6	nc	(nc-nc)	Female	116	100.2	115.7	(95.6-138.8)
<u>Lung and Bronchus</u>									
Male	16	14.8	108.3	(61.9-175.9)					
Female	16	13.6	117.4	(67.0-190.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.8	76.5	(28.0-166.6)	Male	7	4.5	155.0	(62.1-319.5)
Female	2	2.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.3	117.4	(37.8-274.1)
Female	34	29.7	114.3	(79.2-159.8)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.5	nc	(nc-nc)	Male	8	3.2	249.9	(107.6-492.4)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	15	12.0	124.6	(69.7-205.5)	<u>Ovary</u>				
Female	14	9.9	141.9	(77.5-238.2)	Female	3	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	6	2.1	288.9	(105.5-628.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	32.4	64.9	(40.1-99.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	6	2.6	231.5	(84.5-503.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	5	5.9	84.1	(27.1-196.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	96	108.0	88.9	(72.0-108.5)
Female	0	0.5	nc	(nc-nc)	Female	102	93.9	108.6	(88.6-131.9)
<u>Lung and Bronchus</u>									
Male	6	15.2	39.6	(14.5-86.2)					
Female	8	12.3	65.1	(28.0-128.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	104.9	(38.3-228.4)	Male	2	3.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	28	22.2	126.0	(83.7-182.1)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	6	8.8	68.5	(25.0-149.2)	<u>Ovary</u>				
Female	7	8.2	85.5	(34.2-176.1)	Female	2	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	24.4	102.4	(66.2-151.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.0	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	1	4.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	62	78.7	78.8	(60.4-101.0)
Female	0	0.4	nc	(nc-nc)	Female	76	71.7	105.9	(83.5-132.6)
<u>Lung and Bronchus</u>									
Male	9	11.1	81.0	(37.0-153.7)					
Female	17	9.5	178.4	(103.8-285.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	12.1	49.6	(18.1-107.9)
Female	0	0.1	nc	(nc-nc)	Female	10	9.8	101.7	(48.7-187.1)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	3	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.3	70.8	(30.5-139.6)	Male	11	6.9	160.5	(80.0-287.2)
Female	6	4.4	137.8	(50.3-300.0)	Female	6	5.9	101.7	(37.1-221.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	60	51.2	117.2	(89.4-150.8)	Female	8	5.9	135.2	(58.2-266.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	7	5.1	137.5	(55.1-283.4)
<u>Colon / Rectum</u>					Female	3	2.4	nc	(nc-nc)
Male	21	17.7	118.6	(73.4-181.3)	<u>Ovary</u>				
Female	22	17.8	123.9	(77.6-187.5)	Female	6	5.3	113.2	(41.3-246.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	53	49.9	106.1	(79.5-138.8)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	7	5.3	132.1	(52.9-272.1)	Female	1	1.8	nc	(nc-nc)
Female	7	3.4	204.3	(81.8-420.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	10	5.0	200.0	(95.7-367.8)
Male	3	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	10	10.4	96.3	(46.1-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	163	162.6	100.2	(85.4-116.9)
Female	0	0.9	nc	(nc-nc)	Female	181	162.9	111.1	(95.5-128.6)
<u>Lung and Bronchus</u>									
Male	20	22.3	89.6	(54.7-138.3)					
Female	17	21.5	79.1	(46.1-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	7.8	153.8	(79.4-268.6)	Male	4	4.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	5	4.0	125.3	(40.4-292.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	5	1.2	418.7	(134.9-977.0)
Female	3	1.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	37	33.5	110.5	(77.8-152.3)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	6	3.6	167.9	(61.3-365.5)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	21	12.3	171.3	(106.0-261.8)	<u>Ovary</u>				
Female	13	10.6	122.2	(65.0-209.0)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	27	34.8	77.5	(51.0-112.7)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	3.6	195.6	(78.4-403.1)
Male	4	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	9	6.8	132.5	(60.5-251.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.7	nc	(nc-nc)	Male	135	113.5	119.0	(99.7-140.8)
Female	1	0.5	nc	(nc-nc)	Female	121	103.9	116.5	(96.6-139.2)
<u>Lung and Bronchus</u>									
Male	26	15.5	167.3	(109.3-245.2)					
Female	26	13.3	195.6	(127.7-286.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	12	10.4	115.3	(59.5-201.4)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.5	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.2	142.8	(52.1-310.7)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	11.4	96.4	(48.1-172.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	37	38.1	97.2	(68.4-134.0)
Female	0	0.2	nc	(nc-nc)	Female	44	35.1	125.3	(91.1-168.3)
<u>Lung and Bronchus</u>									
Male	8	5.4	147.2	(63.4-290.0)					
Female	4	4.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	105.2	(38.4-228.9)	Male	5	3.9	129.2	(41.6-301.5)
Female	1	1.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	22	21.6	101.6	(63.7-153.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	9	9.2	98.3	(44.9-186.6)	<u>Ovary</u>				
Female	8	6.1	131.9	(56.8-259.9)	Female	5	2.2	230.4	(74.3-537.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	29	25.7	112.7	(75.5-161.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	7	2.9	243.4	(97.5-501.6)	Female	0	0.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.2	nc	(nc-nc)	Female	9	4.4	204.5	(93.3-388.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.4	nc	(nc-nc)	Male	95	85.6	110.9	(89.8-135.6)
Female	1	0.3	nc	(nc-nc)	Female	64	63.8	100.3	(77.2-128.1)
<u>Lung and Bronchus</u>									
Male	12	11.4	105.7	(54.6-184.7)					
Female	4	7.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	25.0	136.0	(94.2-190.0)	Male	16	10.9	146.1	(83.5-237.3)
Female	11	9.2	119.7	(59.7-214.1)	Female	11	8.4	131.5	(65.5-235.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	13	11.0	118.4	(63.0-202.5)
Female	79	78.7	100.4	(79.5-125.1)	Female	8	11.0	72.5	(31.2-142.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	6	7.5	79.9	(29.2-173.9)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	26	36.5	71.3	(46.5-104.4)	<u>Ovary</u>				
Female	47	38.2	123.1	(90.4-163.6)	Female	5	8.6	58.3	(18.8-136.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.7	141.2	(60.8-278.2)	Male	8	6.9	116.8	(50.3-230.1)
Female	0	1.8	nc	(nc-nc)	Female	9	8.2	110.1	(50.2-209.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	127	92.3	137.6	(114.7-163.7)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.2	80.6	(26.0-188.1)
Male	12	8.8	136.7	(70.5-238.8)	Female	3	4.1	nc	(nc-nc)
Female	6	6.1	98.2	(35.9-213.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.4	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.2	95.9	(30.9-223.8)
Male	6	6.8	88.3	(32.2-192.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.0	133.1	(57.3-262.2)	Female	17	16.3	104.6	(60.9-167.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.0	nc	(nc-nc)	Male	339	303.7	111.6	(100.0-124.1)
Female	0	1.8	nc	(nc-nc)	Female	273	283.9	96.2	(85.1-108.3)
<u>Lung and Bronchus</u>									
Male	38	45.6	83.3	(58.9-114.3)					
Female	37	42.2	87.7	(61.8-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	17	15.6	109.1	(63.5-174.7)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	1.7	301.0	(97.0-702.4)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	3	6.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	6.2	81.2	(26.2-189.4)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.3	nc	(nc-nc)	Male	17	17.5	97.1	(56.5-155.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	55	57.4	95.8	(72.1-124.7)
Female	0	0.3	nc	(nc-nc)	Female	47	51.7	90.8	(66.7-120.8)
<u>Lung and Bronchus</u>									
Male	7	8.3	84.5	(33.9-174.2)					
Female	6	7.2	83.2	(30.4-181.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	54.5	77.0	(55.5-104.1)	Male	16	30.1	53.2	(30.4-86.4)
Female	17	22.3	76.3	(44.4-122.2)	Female	16	27.3	58.5	(33.4-95.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.0	90.8	(43.5-167.0)	Male	4	7.9	nc	(nc-nc)
Female	10	10.5	95.3	(45.6-175.3)	Female	6	7.2	82.9	(30.3-180.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	22	28.8	76.4	(47.8-115.6)
Female	217	226.4	95.9	(83.5-109.5)	Female	34	29.1	116.6	(80.8-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	10.5	105.1	(52.4-188.0)	Male	19	20.5	92.5	(55.7-144.4)
<u>Colon / Rectum</u>					Female	9	11.5	78.4	(35.8-148.9)
Male	78	82.7	94.3	(74.6-117.7)	<u>Ovary</u>				
Female	94	93.1	100.9	(81.6-123.5)	Female	22	24.2	90.9	(57.0-137.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	13.4	89.7	(46.3-156.8)	Male	15	15.6	96.4	(53.9-159.0)
Female	9	4.4	203.8	(93.0-386.8)	Female	18	19.6	91.9	(54.5-145.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.0	nc	(nc-nc)	Male	183	211.7	86.5	(74.4-99.9)
Female	6	4.6	130.1	(47.5-283.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	14.1	92.4	(49.2-158.0)
Male	30	22.5	133.4	(90.0-190.5)	Female	11	10.0	110.1	(54.9-197.0)
Female	8	16.1	49.6	(21.4-97.8)	<u>Testis</u>				
<u>Larynx</u>					Male	7	9.5	74.0	(29.7-152.5)
Male	7	9.3	75.4	(30.2-155.4)	<u>Thyroid</u>				
Female	4	2.8	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<u>Leukemia</u>					Female	13	22.5	57.8	(30.7-98.8)
Male	17	17.8	95.4	(55.5-152.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	16.8	83.5	(45.6-140.0)	Female	64	45.0	142.1	(109.4-181.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.5	95.5	(45.7-175.7)	Male	650	725.0	89.7	(82.9-96.8)
Female	4	4.5	nc	(nc-nc)	Female	742	771.0	96.2	(89.4-103.4)
<u>Lung and Bronchus</u>									
Male	96	102.0	94.1	(76.2-114.9)					
Female	101	103.6	97.5	(79.4-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.4	67.1	(21.6-156.7)
Female	0	0.0	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	12.2	81.7	(39.1-150.3)
Female	0	0.0	nc	(nc-nc)	Female	9	9.2	97.3	(44.4-184.7)
<u>Lung and Bronchus</u>									
Male	3	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	22.2	103.4	(65.5-155.2)	Male	22	12.1	181.6	(113.8-275.0)
Female	9	8.5	105.6	(48.2-200.5)	Female	22	10.2	215.8	(135.2-326.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	15	11.5	130.7	(73.1-215.7)
Female	108	91.4	118.2	(97.0-142.7)	Female	9	11.1	81.4	(37.1-154.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.9	nc	(nc-nc)	Male	2	8.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	4.5	133.5	(48.8-290.7)
Male	35	34.1	102.8	(71.6-142.9)	<u>Ovary</u>				
Female	29	35.1	82.7	(55.3-118.7)	Female	8	9.6	83.5	(35.9-164.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.7	139.8	(60.2-275.5)	Male	3	6.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	7	7.4	94.9	(38.0-195.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	89	93.8	94.8	(76.2-116.7)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.7	nc	(nc-nc)
Male	10	9.6	104.2	(49.9-191.6)	Female	0	3.7	nc	(nc-nc)
Female	10	6.3	158.0	(75.7-290.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.7	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.9	126.1	(60.4-231.9)
Male	10	7.0	142.9	(68.4-262.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.2	nc	(nc-nc)	Female	21	18.7	112.1	(69.4-171.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.5	nc	(nc-nc)	Male	274	303.6	90.3	(79.9-101.6)
Female	1	1.7	nc	(nc-nc)	Female	311	299.9	103.7	(92.5-115.9)
<u>Lung and Bronchus</u>									
Male	23	43.1	53.4	(33.8-80.1)					
Female	35	40.7	86.0	(59.9-119.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.3	82.7	(30.2-180.0)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	6	2.5	238.4	(87.1-518.9)	Female	4	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	8.7	126.6	(63.1-226.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	33	27.8	118.9	(81.8-166.9)
Female	0	0.1	nc	(nc-nc)	Female	28	23.2	120.8	(80.2-174.6)
<u>Lung and Bronchus</u>									
Male	1	3.9	nc	(nc-nc)					
Female	3	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	12.9	62.1	(26.8-122.4)	Male	3	6.7	nc	(nc-nc)
Female	6	4.6	129.8	(47.4-282.4)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.5	77.2	(24.9-180.2)
Female	45	47.4	95.0	(69.3-127.1)	Female	6	6.0	100.5	(36.7-218.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	6	4.7	126.7	(46.3-275.9)
<u>Colon / Rectum</u>					Female	4	2.4	nc	(nc-nc)
Male	22	19.4	113.5	(71.1-171.9)	<u>Ovary</u>				
Female	14	18.5	75.8	(41.4-127.1)	Female	7	5.0	139.8	(56.0-288.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.2	188.2	(68.7-409.7)	Male	2	3.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	4.0	126.0	(40.6-294.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	43	52.9	81.3	(58.8-109.5)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.2	154.7	(49.9-361.1)
Male	1	5.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	5	2.2	224.0	(72.2-522.8)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.3	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.2	185.5	(67.7-403.8)	Female	11	9.8	112.5	(56.1-201.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	2.4	204.8	(66.0-478.0)	Male	168	171.7	97.8	(83.6-113.8)
Female	1	0.9	nc	(nc-nc)	Female	163	159.0	102.5	(87.4-119.5)
<u>Lung and Bronchus</u>									
Male	32	24.8	128.9	(88.2-182.0)					
Female	30	22.7	132.1	(89.1-188.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	18.3	92.9	(54.1-148.7)	Male	8	9.8	81.7	(35.2-161.0)
Female	6	6.4	93.7	(34.2-204.0)	Female	7	7.7	90.9	(36.4-187.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.4	145.5	(46.9-339.4)	Male	3	2.7	nc	(nc-nc)
Female	5	3.0	167.9	(54.1-391.9)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	9.4	85.5	(36.8-168.5)
Female	69	68.4	100.9	(78.5-127.7)	Female	6	8.4	71.7	(26.2-156.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	5	7.1	70.1	(22.6-163.7)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	18	27.9	64.5	(38.2-102.0)	<u>Ovary</u>				
Female	19	26.5	71.7	(43.2-112.0)	Female	12	7.2	167.2	(86.3-292.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	57	74.3	76.7	(58.1-99.4)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.7	nc	(nc-nc)
Male	2	7.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.1	131.3	(56.6-258.8)
Male	8	5.7	140.5	(60.5-276.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.7	nc	(nc-nc)	Female	16	13.8	115.7	(66.1-188.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.6	nc	(nc-nc)	Male	188	244.9	76.8	(66.2-88.6)
Female	0	1.3	nc	(nc-nc)	Female	199	225.4	88.3	(76.4-101.4)
<u>Lung and Bronchus</u>									
Male	24	34.8	68.9	(44.1-102.5)					
Female	20	30.6	65.3	(39.9-100.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	2.1	378.1	(162.8-745.0)	Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	5	7.9	63.5	(20.5-148.2)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	9	3.3	270.5	(123.4-513.5)	<u>Ovary</u>				
Female	5	2.4	211.2	(68.1-492.9)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.0	88.4	(38.1-174.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	36	30.2	119.1	(83.4-164.9)
Female	0	0.1	nc	(nc-nc)	Female	26	24.0	108.2	(70.7-158.6)
<u>Lung and Bronchus</u>									
Male	3	4.1	nc	(nc-nc)					
Female	6	3.0	199.1	(72.7-433.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	11.6	138.3	(79.0-224.6)	Male	11	7.3	151.6	(75.6-271.3)
Female	2	3.9	nc	(nc-nc)	Female	7	6.0	116.4	(46.6-239.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	6.7	104.9	(42.0-216.1)
Female	69	51.7	133.3	(103.7-168.8)	Female	4	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.5	200.8	(64.7-468.6)	Male	5	5.5	91.6	(29.5-213.7)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	21	18.3	115.0	(71.2-175.8)	<u>Ovary</u>				
Female	11	15.6	70.4	(35.1-126.1)	Female	3	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	6	3.3	184.4	(67.3-401.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	59	52.8	111.7	(85.0-144.1)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	5	5.6	88.8	(28.6-207.3)	Female	4	1.6	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.4	111.6	(40.8-242.9)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.1	nc	(nc-nc)	Female	12	10.5	114.8	(59.3-200.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.7	nc	(nc-nc)	Male	182	170.2	106.9	(92.0-123.6)
Female	2	0.8	nc	(nc-nc)	Female	171	157.1	108.8	(93.1-126.4)
<u>Lung and Bronchus</u>									
Male	20	23.3	86.0	(52.5-132.8)					
Female	16	20.0	79.9	(45.6-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	43.6	98.7	(71.4-132.9)	Male	14	21.6	64.7	(35.3-108.6)
Female	9	17.4	51.7	(23.6-98.2)	Female	22	18.9	116.5	(73.0-176.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.8	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
Female	5	7.6	66.1	(21.3-154.3)	Female	2	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	15	21.3	70.4	(39.3-116.1)
Female	139	161.0	86.3	(72.6-101.9)	Female	18	21.9	82.0	(48.6-129.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	6.8	117.6	(50.6-231.7)	Male	21	14.7	142.5	(88.2-217.8)
<u>Colon / Rectum</u>					Female	7	8.5	82.5	(33.0-169.9)
Male	73	64.9	112.5	(88.2-141.4)	<u>Ovary</u>				
Female	65	73.6	88.3	(68.1-112.6)	Female	15	17.6	85.3	(47.7-140.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.2	117.3	(60.5-204.8)	Male	10	12.2	82.0	(39.2-150.7)
Female	3	3.5	nc	(nc-nc)	Female	19	15.5	122.5	(73.7-191.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.2	nc	(nc-nc)	Male	128	163.0	78.5	(65.5-93.4)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	11.0	126.8	(69.3-212.8)
Male	13	16.6	78.1	(41.5-133.6)	Female	7	8.0	87.4	(35.0-180.0)
Female	9	12.0	75.1	(34.3-142.6)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.4	111.0	(40.5-241.5)
Male	9	7.0	128.4	(58.6-243.7)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	14.2	56.2	(24.2-110.7)
Male	12	13.5	88.6	(45.7-154.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	12.8	62.3	(26.8-122.7)	Female	43	32.4	132.8	(96.1-178.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.7	91.2	(36.5-187.8)	Male	517	554.6	93.2	(85.4-101.6)
Female	2	3.5	nc	(nc-nc)	Female	522	570.5	91.5	(83.8-99.7)
<u>Lung and Bronchus</u>									
Male	91	80.2	113.4	(91.3-139.3)					
Female	84	78.6	106.9	(85.2-132.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.8	103.0	(41.3-212.2)	Male	2	3.5	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	29	25.4	114.4	(76.6-164.3)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	4	10.2	nc	(nc-nc)	<u>Ovary</u>				
Female	6	10.5	57.0	(20.8-124.1)	Female	2	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	25.3	82.9	(51.3-126.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	7	1.8	386.8	(155.0-797.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.3	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	1	5.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	76	87.3	87.1	(68.6-109.0)
Female	0	0.5	nc	(nc-nc)	Female	78	86.0	90.7	(71.7-113.2)
<u>Lung and Bronchus</u>									
Male	16	12.6	127.4	(72.8-206.9)					
Female	7	11.7	59.7	(23.9-123.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.6	58.4	(18.8-136.2)	Male	7	5.9	118.6	(47.5-244.4)
Female	2	3.1	nc	(nc-nc)	Female	7	5.1	136.5	(54.7-281.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.4	130.5	(52.3-268.8)
Female	48	41.5	115.8	(85.4-153.5)	Female	3	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	8	13.8	58.2	(25.0-114.6)	<u>Ovary</u>				
Female	11	12.7	86.9	(43.3-155.5)	Female	7	4.2	166.7	(66.8-343.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	7	2.6	267.8	(107.3-551.9)
Female	2	0.6	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	37	37.0	99.9	(70.3-137.7)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.3	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	5	3.3	152.5	(49.1-355.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	7	7.9	89.0	(35.6-183.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	117	127.7	91.7	(75.8-109.8)
Female	0	0.6	nc	(nc-nc)	Female	132	126.3	104.5	(87.4-123.9)
<u>Lung and Bronchus</u>									
Male	19	16.9	112.2	(67.5-175.2)					
Female	15	15.1	99.4	(55.6-163.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	2.7	222.8	(81.4-484.9)	Male	0	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	11	11.7	94.3	(47.0-168.7)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.4	145.6	(46.9-339.8)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	12.0	125.0	(69.9-206.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	43	40.3	106.8	(77.2-143.8)
Female	0	0.2	nc	(nc-nc)	Female	35	35.3	99.2	(69.1-138.0)
<u>Lung and Bronchus</u>									
Male	4	5.4	nc	(nc-nc)					
Female	4	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	17.5	126.0	(78.9-190.8)	Male	7	10.1	69.3	(27.8-142.8)
Female	8	6.5	123.9	(53.3-244.1)	Female	10	8.4	119.1	(57.0-219.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	9.5	73.9	(29.6-152.2)
Female	58	71.1	81.5	(61.9-105.4)	Female	7	8.6	81.2	(32.5-167.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	152.1	(49.0-355.0)	Male	5	7.2	69.3	(22.3-161.8)
<u>Colon / Rectum</u>					Female	6	3.5	172.0	(62.8-374.3)
Male	37	26.9	137.6	(96.9-189.7)	<u>Ovary</u>				
Female	25	26.1	95.9	(62.1-141.6)	Female	7	7.4	94.1	(37.7-193.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.5	110.0	(35.4-256.7)	Male	5	5.1	97.9	(31.6-228.5)
Female	0	1.3	nc	(nc-nc)	Female	6	5.5	108.7	(39.7-236.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	70	74.6	93.9	(73.2-118.6)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.5	nc	(nc-nc)
Male	7	7.7	90.4	(36.2-186.2)	Female	2	2.7	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.0	164.1	(52.9-382.9)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.0	nc	(nc-nc)
Male	9	5.7	157.3	(71.8-298.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.8	126.0	(46.0-274.3)	Female	14	14.5	96.5	(52.7-162.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.6	nc	(nc-nc)	Male	249	243.9	102.1	(89.8-115.6)
Female	0	1.3	nc	(nc-nc)	Female	221	232.9	94.9	(82.8-108.3)
<u>Lung and Bronchus</u>									
Male	43	34.1	126.1	(91.2-169.9)					
Female	39	31.8	122.5	(87.1-167.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	11.6	164.3	(98.9-256.6)	Male	13	6.6	196.5	(104.5-336.0)
Female	9	3.9	230.6	(105.2-437.8)	Female	5	5.4	92.4	(29.8-215.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.2	96.7	(35.3-210.4)
Female	59	46.9	125.9	(95.8-162.4)	Female	8	5.3	150.3	(64.7-296.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	8	4.8	165.4	(71.2-325.9)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	23	17.9	128.8	(81.6-193.2)	<u>Ovary</u>				
Female	22	15.6	141.1	(88.4-213.7)	Female	9	4.8	187.1	(85.4-355.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	50	49.6	100.7	(74.7-132.8)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	6	3.1	192.8	(70.4-419.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	5	2.1	233.2	(75.2-544.2)	<u>Thyroid</u>				
Female	2	0.6	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.6	129.9	(47.4-282.8)
Male	7	3.7	189.2	(75.8-389.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.9	nc	(nc-nc)	Female	9	9.6	93.5	(42.7-177.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.4	nc	(nc-nc)	Male	194	161.1	120.4	(104.0-138.6)
Female	2	0.8	nc	(nc-nc)	Female	199	147.4	135.0	(116.9-155.2)
<u>Lung and Bronchus</u>									
Male	26	22.6	115.2	(75.3-168.9)					
Female	42	19.7	213.2	(153.6-288.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	12	7.8	153.7	(79.3-268.6)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	8.6	57.9	(18.7-135.2)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.8	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	28.4	88.0	(57.0-130.0)
Female	0	0.1	nc	(nc-nc)	Female	30	24.7	121.2	(81.8-173.1)
<u>Lung and Bronchus</u>									
Male	3	3.9	nc	(nc-nc)					
Female	4	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.0	106.9	(61.1-173.7)	Male	9	8.2	110.2	(50.3-209.3)
Female	4	6.0	nc	(nc-nc)	Female	9	6.9	130.1	(59.4-246.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	7.7	116.6	(53.2-221.3)
Female	69	61.8	111.6	(86.9-141.3)	Female	7	7.7	91.0	(36.4-187.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	3.1	nc	(nc-nc)
Male	18	22.9	78.6	(46.6-124.3)	<u>Ovary</u>				
Female	31	24.9	124.6	(84.7-176.9)	Female	6	6.5	91.9	(33.6-200.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.1	nc	(nc-nc)	Male	66	61.8	106.7	(82.5-135.8)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	12	6.4	187.8	(96.9-328.1)	Female	2	2.6	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.9	268.7	(86.6-627.0)
Male	1	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.3	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.3	140.8	(51.4-306.5)	Female	14	12.5	111.6	(61.0-187.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.0	nc	(nc-nc)	Male	196	202.5	96.8	(83.7-111.3)
Female	0	1.2	nc	(nc-nc)	Female	223	206.3	108.1	(94.4-123.3)
<u>Lung and Bronchus</u>									
Male	24	28.9	83.1	(53.2-123.7)					
Female	36	28.2	127.4	(89.2-176.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.3	114.2	(62.4-191.6)	Male	10	6.6	151.8	(72.7-279.3)
Female	12	4.5	267.7	(138.2-467.7)	Female	5	5.5	90.8	(29.3-211.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.3	79.0	(25.5-184.4)
Female	52	46.6	111.6	(83.3-146.3)	Female	6	5.9	102.3	(37.3-222.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	20	18.6	107.6	(65.7-166.1)	<u>Ovary</u>				
Female	14	18.8	74.5	(40.7-125.0)	Female	9	4.9	182.0	(83.1-345.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	7	3.5	199.7	(80.0-411.4)
Female	1	0.9	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	48	47.4	101.3	(74.7-134.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	9	5.0	179.3	(81.8-340.4)	Female	4	2.0	nc	(nc-nc)
Female	6	3.3	183.5	(67.0-399.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.7	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.5	156.0	(62.5-321.4)
Male	1	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.4	nc	(nc-nc)	Female	2	9.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	182	161.4	112.8	(97.0-130.4)
Female	0	0.9	nc	(nc-nc)	Female	161	156.5	102.9	(87.6-120.0)
<u>Lung and Bronchus</u>									
Male	34	22.9	148.2	(102.6-207.1)					
Female	18	20.9	86.3	(51.1-136.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.1	110.2	(52.8-202.7)	Male	4	5.3	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	7	4.4	158.1	(63.3-325.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	31	37.6	82.4	(56.0-117.0)	Female	4	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	7	3.8	182.5	(73.1-376.1)
<u>Colon / Rectum</u>					Female	0	1.8	nc	(nc-nc)
Male	18	14.0	128.4	(76.1-203.0)	<u>Ovary</u>				
Female	10	14.1	71.1	(34.1-130.8)	Female	0	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	37	38.0	97.3	(68.5-134.1)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	5	4.1	123.4	(39.8-287.9)	Female	0	1.5	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.7	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.6	nc	(nc-nc)	Female	8	7.4	107.7	(46.4-212.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	133	126.2	105.4	(88.2-124.9)
Female	0	0.7	nc	(nc-nc)	Female	98	122.4	80.0	(65.0-97.5)
<u>Lung and Bronchus</u>									
Male	24	17.5	137.2	(87.9-204.1)					
Female	16	15.9	100.9	(57.6-163.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	6.3	nc	(nc-nc)	Male	6	4.0	148.7	(54.3-323.6)
Female	4	2.2	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	23	23.9	96.1	(60.9-144.3)	Female	1	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	8	9.9	80.8	(34.8-159.1)	<u>Ovary</u>				
Female	8	9.2	87.2	(37.5-171.7)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	22	26.5	82.9	(51.9-125.5)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	6	4.8	125.6	(45.9-273.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	72	90.6	79.5	(62.2-100.1)
Female	0	0.4	nc	(nc-nc)	Female	76	79.1	96.1	(75.7-120.2)
<u>Lung and Bronchus</u>									
Male	11	12.3	89.8	(44.7-160.6)					
Female	11	10.4	105.9	(52.8-189.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	12.4	153.5	(92.4-239.7)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	5	5.4	91.8	(29.6-214.3)	<u>Ovary</u>				
Female	5	4.4	114.3	(36.8-266.8)	Female	2	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	14.9	100.7	(56.3-166.2)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	46	48.5	94.9	(69.5-126.6)
Female	1	0.2	nc	(nc-nc)	Female	45	39.7	113.4	(82.7-151.8)
<u>Lung and Bronchus</u>									
Male	4	6.9	nc	(nc-nc)					
Female	3	5.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	53.5	80.4	(58.2-108.3)	Male	14	30.2	46.4	(25.3-77.8)
Female	26	21.8	119.5	(78.0-175.1)	Female	12	28.2	42.6	(22.0-74.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	12.0	92.0	(45.9-164.7)	Male	5	7.8	64.2	(20.7-149.9)
Female	10	11.3	88.5	(42.4-162.8)	Female	4	7.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	26	29.1	89.2	(58.3-130.8)
Female	162	224.6	72.1	(61.4-84.1)	Female	33	29.1	113.4	(78.0-159.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	26	10.8	240.8	(157.3-352.9)	Male	30	20.3	147.6	(99.6-210.7)
<u>Colon / Rectum</u>					Female	8	11.5	69.9	(30.1-137.7)
Male	84	81.2	103.4	(82.5-128.0)	<u>Ovary</u>				
Female	73	91.2	80.0	(62.7-100.6)	Female	25	24.2	103.2	(66.8-152.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	13.1	106.9	(58.4-179.3)	Male	23	15.3	150.6	(95.5-226.0)
Female	8	4.3	185.5	(79.9-365.5)	Female	14	19.1	73.3	(40.0-122.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.9	102.4	(37.4-222.9)	Male	193	206.6	93.4	(80.7-107.6)
Female	7	5.5	126.2	(50.5-259.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	19	13.9	137.0	(82.5-214.0)
Male	11	22.3	49.4	(24.6-88.5)	Female	6	9.8	61.1	(22.3-133.0)
Female	10	16.0	62.4	(29.9-114.7)	<u>Testis</u>				
<u>Larynx</u>					Male	6	11.0	54.6	(19.9-118.8)
Male	9	9.1	99.0	(45.2-188.0)	<u>Thyroid</u>				
Female	5	2.8	181.6	(58.5-423.9)	Male	3	6.6	nc	(nc-nc)
<u>Leukemia</u>					Female	16	24.2	66.2	(37.8-107.6)
Male	18	18.7	96.3	(57.0-152.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	17.6	85.3	(47.7-140.6)	Female	50	44.5	112.4	(83.4-148.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	10.3	135.5	(74.0-227.4)	Male	688	718.8	95.7	(88.7-103.1)
Female	5	4.5	112.2	(36.1-261.7)	Female	657	768.1	85.5	(79.1-92.3)
<u>Lung and Bronchus</u>									
Male	112	99.7	112.3	(92.5-135.2)					
Female	80	101.2	79.1	(62.7-98.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.7	nc	(nc-nc)	Male	9	4.0	227.0	(103.6-430.9)
Female	2	2.7	nc	(nc-nc)	Female	5	3.1	161.7	(52.1-377.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	34	27.5	123.8	(85.7-173.0)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.4	nc	(nc-nc)
Male	16	11.6	138.3	(79.0-224.6)	<u>Ovary</u>				
Female	23	11.1	207.8	(131.7-311.8)	Female	0	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	24	31.2	77.0	(49.3-114.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	7	3.1	224.8	(90.1-463.2)	Female	0	1.2	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	5.6	160.0	(73.0-303.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.4	nc	(nc-nc)	Male	103	101.6	101.4	(82.7-123.0)
Female	2	0.5	nc	(nc-nc)	Female	113	92.5	122.2	(100.7-146.9)
<u>Lung and Bronchus</u>									
Male	16	14.7	109.1	(62.3-177.2)					
Female	15	13.1	114.9	(64.3-189.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.2	108.0	(53.9-193.3)	Male	2	5.7	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.4	92.4	(29.8-215.7)
Female	45	39.4	114.1	(83.2-152.7)	Female	5	4.9	102.6	(33.0-239.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.8	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	15	15.5	96.7	(54.1-159.6)	<u>Ovary</u>				
Female	13	15.1	86.2	(45.9-147.5)	Female	4	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	40	40.6	98.5	(70.4-134.2)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.6	308.5	(99.4-719.8)
Male	4	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.9	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.7	nc	(nc-nc)	Female	7	7.9	88.6	(35.5-182.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	129	137.0	94.2	(78.6-111.9)
Female	0	0.7	nc	(nc-nc)	Female	134	130.7	102.5	(85.9-121.4)
<u>Lung and Bronchus</u>									
Male	15	19.3	77.8	(43.5-128.4)					
Female	28	17.6	158.9	(105.6-229.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	8.3	204.3	(119.0-327.2)	Male	3	3.9	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	5	3.2	156.6	(50.5-365.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	3.8	235.5	(107.5-447.1)
Female	26	29.6	87.8	(57.3-128.7)	Female	5	4.1	121.5	(39.2-283.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	11	12.3	89.4	(44.6-160.0)	<u>Ovary</u>				
Female	23	14.6	157.2	(99.6-236.0)	Female	2	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	25	30.8	81.1	(52.5-119.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.1	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	5	6.0	83.3	(26.8-194.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	108	102.8	105.1	(86.2-126.9)
Female	0	0.7	nc	(nc-nc)	Female	99	106.4	93.0	(75.6-113.2)
<u>Lung and Bronchus</u>									
Male	13	15.0	86.9	(46.2-148.6)					
Female	11	14.9	73.6	(36.7-131.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	41.6	93.8	(66.7-128.2)	Male	10	22.6	44.2	(21.1-81.2)
Female	17	16.0	105.9	(61.7-169.6)	Female	7	19.5	35.9	(14.4-74.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	8.2	97.9	(42.1-192.8)	Male	4	6.0	nc	(nc-nc)
Female	4	7.5	nc	(nc-nc)	Female	6	5.2	114.6	(41.8-249.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	27	21.7	124.5	(82.0-181.2)
Female	133	164.1	81.0	(67.9-96.1)	Female	21	21.0	100.1	(62.0-153.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	7.4	94.3	(37.8-194.3)	Male	16	15.7	101.9	(58.2-165.5)
<u>Colon / Rectum</u>					Female	8	8.3	96.6	(41.6-190.4)
Male	71	63.1	112.6	(87.9-142.0)	<u>Ovary</u>				
Female	73	66.3	110.1	(86.3-138.4)	Female	19	17.5	108.8	(65.5-169.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.3	106.8	(53.2-191.0)	Male	16	11.9	134.5	(76.8-218.4)
Female	2	3.2	nc	(nc-nc)	Female	11	14.0	78.5	(39.1-140.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.6	168.0	(61.3-365.6)	Male	143	166.4	85.9	(72.4-101.2)
Female	1	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	10.6	122.5	(65.2-209.5)
Male	17	17.3	98.4	(57.3-157.5)	Female	14	7.0	199.3	(108.9-334.4)
Female	8	11.7	68.3	(29.4-134.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.6	136.9	(62.5-259.9)
Male	9	7.2	125.0	(57.0-237.3)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	12	15.8	75.9	(39.2-132.6)
Male	16	13.4	119.8	(68.4-194.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	11.9	67.4	(29.0-132.8)	Female	27	33.0	81.9	(54.0-119.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.0	99.8	(43.0-196.7)	Male	544	557.0	97.7	(89.6-106.2)
Female	2	3.2	nc	(nc-nc)	Female	471	555.6	84.8	(77.3-92.8)
<u>Lung and Bronchus</u>									
Male	80	79.2	100.9	(80.0-125.6)					
Female	62	76.0	81.6	(62.5-104.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;